Skip to main content
BOTANIX PHARMACEUTICALS LTD logo

BOTANIX PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · BOT ISIN · AU000000BOT2 ASX Manufacturing
Open in API
Filings indexed 1,208 across all filing types
Latest filing 2023-07-30 Interim / Quarterly Rep…
Country AU Australia
Listing ASX BOT

About BOTANIX PHARMACEUTICALS LTD

https://botanixpharma.com/

Botanix Pharmaceuticals Ltd is a clinical-stage pharmaceutical company focused on the development and commercialization of novel topical treatments for serious skin conditions. The company utilizes its proprietary Permetrex™ skin delivery technology, which is designed to improve the delivery of active ingredients through the skin. Its primary product, Sofdra™ (sofpironium bromide), is an FDA-approved prescription topical gel for the treatment of primary axillary hyperhidrosis. The company's research and development pipeline also includes clinical-stage candidates for the treatment of acne, rosacea, and atopic dermatitis. Botanix aims to address significant unmet medical needs in dermatology by providing innovative therapeutic solutions with enhanced safety and efficacy profiles.

Recent filings

Filing Released Lang Actions
June 2023 Quarterly Activities Report and Appendix 4C 9 pages 667.4KB
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "Quarterly Activity Report and 4C Quarterly Cash Flow Report" for the period ended 30 June 2023. It contains detailed financial data including cash flows from operating, investing, and financing activities, as well as narrative on corporate activities, FDA approval progress, and capital raising. The presence of the Appendix 4C cash flow report, which is a regulatory quarterly financial report for Australian listed entities, confirms this is a comprehensive interim financial report. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. Therefore, this document fits the definition of an Interim / Quarterly Report (IR).
2023-07-30 English
Application for quotation of securities - BOT 6 pages 28.0KB
Capital/Financing Update Classification · 100% confidence The document is an application for quotation of securities on the ASX by Botanix Pharmaceuticals Ltd. It details the number and type of securities to be quoted, issue dates, and references previous announcements such as Appendix 3B. The content focuses on the issuance and quotation of new shares and options, including pricing and distribution schedules. There is no financial performance data, management discussion, or audit information. The document is clearly about capital market activity related to new securities issuance and quotation. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a report publication notice but a substantive update on capital structure changes.
2023-07-26 English
Notification regarding unquoted securities - BOT 7 pages 31.4KB
Share Issue/Capital Change Classification · 100% confidence The document is a detailed notification about the issue of unquoted equity securities, specifically options exercisable at a certain price and expiring on a future date. It includes specifics such as the number of securities issued, the issue date, the nature of the securities, and references to related ASX announcements and Appendix 3B filings. The content focuses on the issuance of new securities and related compliance with listing rules, rather than financial results, management changes, or other report types. This matches the definition of a Share Issue/Capital Change filing, which covers announcements regarding new share issues or capital changes. The document length and detail confirm it is the announcement itself, not a brief notice or a report publication announcement.
2023-07-26 English
Botanix Closes Capital Raising and Royalty Milestone Buyout 3 pages 198.3KB
Capital/Financing Update Classification · 95% confidence The document is an announcement dated 27 July 2023 from Botanix Pharmaceuticals about completing a A$12.5 million placement and executing a buyout agreement related to milestone and royalty payments for Sofpironium Bromide. It details the issuance of new shares, the use of proceeds, and strategic positioning for potential M&A and licensing opportunities. The content focuses on fundraising and capital structure changes, including share issuance and financial arrangements with Fresh Tracks Therapeutics. There are no financial statements or detailed financial performance data presented, nor is this a transcript, report, or regulatory filing of a different nature. The document fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes.
2023-07-26 English
Section 708A(5)(e) Notice 2 pages 157.5KB
Capital/Financing Update Classification · 95% confidence The document is a notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) regarding the issuance of new shares by Botanix Pharmaceuticals Limited. It provides legal and regulatory disclosure about the share issue, including compliance statements and exemption details. The document does not contain financial statements, management discussion, or detailed financial results. It is a formal announcement about a capital raising event (placement of new shares) and the associated regulatory notice. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 3492 characters, which is consistent with a notice rather than a full report. Hence, the classification is CAP with high confidence.
2023-07-26 English
Botanix Bioshares Biotech Summit Presentation 14 pages 1.2MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation by Botanix Pharmaceuticals at the Bioshares Biotech Summit, dated 24 July 2023. It includes company background, product pipeline, market potential, regulatory status (FDA approval timeline), and forward-looking statements. The text explicitly states it is a presentation being presented at a conference and includes slides and graphics descriptions. There are no financial statements or earnings data, nor is it an announcement of voting results, management changes, or legal matters. The content is focused on investor and industry information about the company's strategy, products, and market outlook. Therefore, this document fits the definition of an Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2023-07-23 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.